Comparing efficacy, subject satisfaction, and safety of Food and Drug Administration–approved neuromodulators in facial aesthetics.
Background: Neuromodulators are widely used in facial aesthetics, offering nonsurgical options for addressing wrinkles and rejuvenating the face. Currently, 6 FDA-approved botulinum toxin A (BoNTA) formulations are available: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumt...
| Publicado en: | Journal of Dermatology for Physician Assistants Vol. 20; no. 1; pp. 3 - 10 |
|---|---|
| Autores principales: | , |
| Formato: | CEU research systematic review tables/charts Journal Article |
| Publicado: |
Society of Dermatology Physician Assistants
Winter2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191725526&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191725526 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 19389574 N3ST jtl: Journal of Dermatology for Physician Assistants issn: 19389574 maglogo: N pubinfo: dt: Winter2026 vid: 20 iid: 1 pid: 72069 pub: Society of Dermatology Physician Assistants place: Alexandria, Virginia artinfo: ui: 191725526 191725526 191725526 10.1097/jdpa.0000000000000092 191725526 ppf: 3 ppct: 7 formats: tig: atl: Comparing efficacy, subject satisfaction, and safety of Food and Drug Administration–approved neuromodulators in facial aesthetics. aug: au: Napoletano, Justin Dempsey, Shea affil: Shenandoah University, Division of Physician Assistant Studies, Winchester, Virginia. sug: subj: Botulinum Toxins Drug Efficacy Patient Satisfaction Patient Safety United States Food and Drug Administration Neurotransmitters Aesthetics Face Human Education, Medical, Continuing Injections, Intradermal Cosmetic Techniques Education, Continuing (Credit) PubMed Systematic Review ab: Background: Neuromodulators are widely used in facial aesthetics, offering nonsurgical options for addressing wrinkles and rejuvenating the face. Currently, 6 FDA-approved botulinum toxin A (BoNTA) formulations are available: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, daxibotulinumtoxinA, and letibotulinumtoxinA. However, no comprehensive analysis has directly compared their duration of efficacy, patient satisfaction, and safety profiles. Methods: A literature search of PubMed was conducted, identifying studies from the last 10 years evaluating neuromodulators in facial aesthetics. Inclusion criteria required studies to report on efficacy, duration of results, or safety profiles. Exclusion criteria included studies not focusing on facial aesthetic applications, those not differentiating between neuromodulators, meta-analyses, and studies combining BoNTA with other treatments. Data on investigator-determined responder rates at 30, 60, 90, and 120+ days, as well as subject satisfaction and adverse events, were extracted. Results: A total of 82 studies met the inclusion criteria. All neuromodulators demonstrated peak efficacy at 30 days, followed by a gradual decline. At day 30, mean responder rates ranged from 64.7% (letibotulinumtoxinA) to 95.6% (daxibotulinumtoxinA). At day 120, these ranged from 10.6% (letibotulinumtoxinA) to 65.2% (incobotulinumtoxinA). LetibotulinumtoxinA and prabotulinumtoxinA had the lowest responder rates, though limited study availability and differing methodology likely influenced these findings. Subject satisfaction showed a similar pattern, peaking at 30 days, though declining more slowly over time. At day 30, subject satisfaction rates ranged from 86.1% (onabotulinumtoxinA) to 97.4% (incobotulinumtoxinA). At day 120, these ranged from 74.2% (prabotulinumtoxinA) to 93% (incobotulinumtoxinA). There were no studies for daxibotulinumtoxinA or letibotulinumtoxinA that disclosed subject satisfaction rates, so they were excluded from this analysis. No serious treatment-related adverse events were reported. Mild, transient side effects were largely related to injection site reactions, such as bruising and erythema. Conclusion: All 6 FDA-approved neuromodulators are safe and effective for facial rejuvenation, with differences in responder rates and longevity potentially influenced by study methodologies. Injector skill, dosing, and patient-specific factors remain critical in optimizing outcomes. Further research is necessary to standardize assessment tools, conduct head-to-head trials, and evaluate long-term efficacy in diverse populations. pubtype: Academic Journal doctype: CEU research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|